3/18
07:48 am
fold
Rating for FOLD
Low
Report
Rating for FOLD
2/29
02:34 pm
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $22.00 price target on the stock.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $22.00 price target on the stock.
2/29
01:46 pm
fold
Rating for FOLD
Low
Report
Rating for FOLD